ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
生物科技指數ETF-iShares Nasdaq
202.93
+0.2900
0.14%
盤後：
203.02
0.0900
+0.04%
19:37 EDT
成交量：
228.63萬
成交額：
4.65億
市值：
102.78億
市盈率：
32.15
高：
205.31
開：
203.94
低：
202.75
收：
202.64
52周最高：
217.12
52周最低：
138.79
股本：
5,065.00萬
流通股本：
5,065.00萬
量比：
1.60
換手率：
4.51%
股息：
0.41
股息率：
0.20%
每股收益(TTM):
6.31
每股收益(LYR):
-1.4940
淨資產收益率：
24.54%
總資產收益率：
0.10%
市淨率：
1.26
市盈率(LYR):
-135.83
資料載入中...
總覽
公司
新聞
公告
福泰製藥(VRTX)股票8月19日收盤上漲4.48%：釋放什麼信號？
TradingKey中文
·
08/20
吉利德科學(GILD)股票8月19日盤中上漲3.66%：背後推手曝光
TradingKey中文
·
08/20
安進(AMGN)股票8月19日盤中上漲3.19%：背後推手曝光
TradingKey中文
·
08/20
再生元製藥旗下Pasatru獲歐洲藥品管理局審評，全球申報在即
美股速递
·
08/20
再生元製藥獲FDA批准：Pasatru（Garetosmab-Grts）上市，治療成人進行性骨化性纖維發育不良
美股速递
·
08/20
異動解讀｜生物科技指數ETF-iShares Nasdaq盤中上漲5.1%，MNC併購加速疊加多重利好共振
行情直击
·
08/19
瑞穗上調安進目標價至352美元
格隆汇
·
08/19
駿利亨德森投資：專利到期倒逼藥企擴張 生物科技併購、IPO市場同步復甦
智通财经网
·
08/19
藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」
蓝鲸财经
·
08/19
TScan Therapeutics披露：安進將終止與其研究合作及許可協議
美股速递
·
08/19
吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光
TradingKey中文
·
08/19
argenx SE(ARGX)股票8月17日盤中上漲16.67%：關鍵驅動因素揭曉
TradingKey中文
·
08/18
EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標
路透中文
·
08/17
美股開盤 | 三大指數升跌不一，閃迪升逾3%，Argenx SE漲近9%
老虎资讯综合
·
08/17
EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌
路透中文
·
08/17
美股異動 | Argenx(ARGX.US)盤前升逾10% 自身免疫性肌炎藥物Vyvgart III期研究達主要終點
智通财经
·
08/17
美股異動丨Argenx SE盤前大升逾7%，Efgartigimod治療肌炎III期試驗成功
中金财经
·
08/17
復星醫藥子公司攜生物類似藥出海 牽手全球仿製藥龍頭，鎖定四成銷售分成
每日经济新闻
·
08/17
復宏漢霖與山德士達成戰略合作
智通财经
·
08/17
argenx SE（ARGX）宣佈Efgartigimod治療自身免疫性肌炎的3期ALKIVIA試驗取得積極結果
金吾财讯
·
08/17
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/IBB/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指數ETF-iShares Nasdaq","latestPrice":202.93,"timestamp":1789156800000,"preClose":202.64,"halted":0,"volume":2286306,"hourTrading":{"tag":"盘后","latestPrice":203.02,"preClose":202.93,"latestTime":"19:37 EDT","volume":32362,"amount":6567264.34,"timestamp":1789169879648,"change":0.09,"changeRate":0.000444,"amplitude":0.000444},"delay":0,"changeRate":0.0014311093564943766,"floatShares":50650000,"shares":50650000,"eps":6.311863,"marketStatus":"休市中","change":0.29,"latestTime":"09-11 16:00:00 EDT","open":203.94,"high":205.31,"low":202.75,"amount":465174036.47682,"amplitude":0.012633,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":202.64,"sharesOutstanding":49450000,"nav":202.867176,"aum":10356369334.8,"dividendRate":0.001997,"bidAskSpread":0.000338,"preHourTrading":{"tag":"盘前","latestPrice":204.63,"preClose":202.64,"latestTime":"09:25 EDT","volume":602,"amount":123106.38130000001,"timestamp":1789133112066,"change":1.99,"changeRate":0.00982,"amplitude":0.017917},"postHourTrading":{"tag":"盘后","latestPrice":203.02,"preClose":202.93,"latestTime":"19:37 EDT","volume":32362,"amount":6567264.34,"timestamp":1789169879648,"change":0.09,"changeRate":0.000444,"amplitude":0.000444},"volumeRatio":1.6013834487935477,"impliedVol":0.2368,"impliedVolPercentile":0.5299},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":50650000,"roa":"0.10%","roe":"24.54%","lyrEps":-1.493977,"volumeRatio":1.6013834487935477,"shares":50650000,"dividePrice":0.4053,"high":205.31,"amplitude":0.012633,"preClose":202.64,"low":202.75,"week52Low":138.785,"pbRate":"1.26","psRate":"247.29","week52High":217.12,"institutionHeld":0,"latestPrice":202.93,"eps":6.311863,"divideRate":0.001997,"volume":2286306,"delay":0,"ttmEps":6.311863,"open":203.94,"prevYearClose":168.77,"prevWeekClose":211.92,"prevMonthClose":209.05,"prevQuarterClose":190.19,"fiveDayClose":213.81,"twentyDayClose":198.94,"sixtyDayClose":171.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"},{"date":"2025-03-18","symbol":"IBB","amount":0.121169,"announcedDate":"2025-03-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-18","defaultRemindTime":1742304600000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-03-18","currency":"USD","dateTimestamp":1742270400000,"payDate":"2025-03-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-26","recordDate":"2016-09-28","paymentDate":"2016-09-30","value":0.0858219,"currency":"USD"},{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660473644","title":"福泰製藥(VRTX)股票8月19日收盤上漲4.48%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660473644","media":"TradingKey中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660473644?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 04:16","pubTimestamp":1787170582,"startTime":"0","endTime":"0","summary":"• 在竞争对手临床试验宣告失败后，福泰制药股价飙升至历史新高。\n• 第二季度营收超出预期，公司同时上调了全年业绩指引。\n• 分析师纷纷给出看涨评级，平均目标价达 563.25 美元。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262119125-market-movers-vrtx-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU1035775433.USD","LU2324357040.USD","LU2468319806.SGD","VRTX","LU0432979614.USD","BBH","LU1778281490.HKD","IE00B19Z3B42.SGD","LU2237438978.USD","IE00B4R5TH58.HKD","SG9999001176.SGD","IE0002270589.USD","IE00BJT1NW94.SGD","LU0058720904.USD","LU1585245621.USD","IDNA","IE0009355771.USD","IE00B19Z3581.USD","SGXZ57979304.SGD","IE00B19Z9Z06.USD","LU2456880835.USD","LU0417517546.SGD","LU2462157665.USD","IBB","LU1093756325.SGD","GNMX","LU0079474960.USD","LU0256863811.USD","PBE","BIB","LU2362541513.USD","BK4588","LU1674673428.USD","LU0823416689.USD","BK4532","LU2417539215.USD","LU0234570918.USD","BK4139","LU2362541273.HKD","IBBQ","LU0109394709.USD","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU1674673691.USD","BK4567","LU2236285917.USD","LU0289739699.SGD","LU0320765992.SGD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660113478","title":"吉利德科學(GILD)股票8月19日盤中上漲3.66%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660113478","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660113478?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 03:17","pubTimestamp":1787167048,"startTime":"0","endTime":"0","summary":"• 得益于HIV产品组合增长加速，吉利德上调了全年销售指引。\n• 联邦法院颁布禁令阻止海外进口，以保护其核心市场份额。\n• 分析师给予“买入”评级，平均目标价为157.79美元。","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262118864-market-movers-gild-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU0965509101.SGD","BBH","BK4583","LU0058720904.USD","LU1057294990.SGD","LU1674673428.USD","LU2468319806.SGD","LU0289739699.SGD","BMED","LU0965508806.USD","LU2324357040.USD","LU0965509283.SGD","LU1934455194.USD","LU1839511570.USD","LU1934455863.HKD","SG9999015986.USD","LU1585245621.USD","BK4139","IE00BKVL7J92.USD","SG9999015952.SGD","LU1934455277.USD","TBXU","BK4532","LU0965509010.AUD","LU1778281490.HKD","TMED","BIB","BK4588","SG9999015978.USD","GILD","LU1023059063.AUD","IBBQ","LU0823416689.USD","LU1674673691.USD","IE00B7SZLL34.SGD","LU0234570918.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","IBB","IE0002270589.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","BK4578","BK4550","MEDI","LU1037948541.HKD","SG9999015945.SGD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660819420","title":"安進(AMGN)股票8月19日盤中上漲3.19%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660819420","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660819420?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 02:16","pubTimestamp":1787163383,"startTime":"0","endTime":"0","summary":"• Argus上调安进目标价，并重申“买入”评级。\n• 第二季度财务业绩超出华尔街的营收和盈利预期。\n• 技术指标显示 MACD 买入信号及 RSI 买入条件。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262118749-market-movers-amgn-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0122379950.USD","TBXU","PJP","SG9999001440.SGD","IBB","LU0289739699.SGD","IE00B2B36J28.USD","BK4585","BIB","BK4533","BK4534","LU0320765992.SGD","LU2242646821.SGD","BBH","AMGN","LU0058720904.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","PBE","LU1983299246.USD","BK4139","LU2468319806.SGD","LU1061106388.HKD","BK4566","IE00B4R5TH58.HKD","LU2242652126.USD","BK4581","IE0002141913.USD","LU1571399168.USD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU0868494617.USD","IBBQ","LU1057294990.SGD","LU2112291526.USD","BK4599","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105025052","title":"再生元製藥旗下Pasatru獲歐洲藥品管理局審評，全球申報在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1105025052","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105025052?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 02:00","pubTimestamp":1787162410,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其研发的药物Pasatru已被欧洲药品管理局纳入审评流程。与此同时，该公司正积极筹备在全球范围内提交该药物的上市申请。欧洲药品管理局的审评启动，为这款药物在欧洲地区的获批前景增添了重要砝码。业界分析认为，Pasatru若能顺利通过审评，有望为相关疾病领域带来新的治疗选择。再生元制药在创新药物研发领域深耕多年，此次针对Pasatru的全球布局，也彰显了其对这一候选药物商业潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","REGN","LU0058720904.USD","LU1974910355.USD","LU0823434583.USD","LU0882574055.USD","LU0823434740.USD","TBXU","LU0320765992.SGD","LU0289739699.SGD","LU0109394709.USD","LU2237438978.USD","LU0889565916.HKD","BK4139","LU0114720955.EUR","BK4585","LU1917777945.USD","LU2468319806.SGD","LU2362541273.HKD","LU2089984988.USD","LU2362540622.SGD","LU0823416689.USD","LU0053666078.USD","IBBQ","LU2362541513.USD","LU2023250504.SGD","BBH","LU2106854487.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188134905","title":"再生元製藥獲FDA批准：Pasatru（Garetosmab-Grts）上市，治療成人進行性骨化性纖維發育不良","url":"https://stock-news.laohu8.com/highlight/detail?id=1188134905","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188134905?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 01:59","pubTimestamp":1787162353,"startTime":"0","endTime":"0","summary":"再生元制药公司今日宣布，其研发的新药Pasatru已获得美国食品药品监督管理局的正式批准，用于治疗成人进行性骨化性纤维发育不良。这一罕见疾病此前一直缺乏有效的治疗手段，此次获批为患者带来了新的希望。FDA的此次批准基于多项临床研究数据，结果显示Pasatru在减缓异位骨化进展方面表现出显著疗效，且安全性可控。未来，再生元制药计划进一步拓展Pasatru的适应症范围，并探索其在其他相关疾病中的潜在应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","BBH","LU2468319806.SGD","LU0882574055.USD","LU2237438978.USD","LU2362541273.HKD","LU0058720904.USD","LU0823434740.USD","REGN","IBB","LU0320765992.SGD","LU0823416689.USD","LU0053666078.USD","LU0823434583.USD","LU1917777945.USD","LU0109394709.USD","LU0114720955.EUR","LU0889565916.HKD","LU2106854487.HKD","BK4585","LU2362541513.USD","LU0289739699.SGD","BK4139","IBBQ","LU2023250504.SGD","TBXU","LU2362540622.SGD","BK4588","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187101531","title":"異動解讀｜生物科技指數ETF-iShares Nasdaq盤中上漲5.1%，MNC併購加速疊加多重利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1187101531","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187101531?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:09","pubTimestamp":1787148587,"startTime":"0","endTime":"0","summary":"8月19日，生物科技指数ETF-iShares Nasdaq盘中上涨5.1%，报213.88美元，成交额1.03亿美元。消息面上，生物科技板块近期迎来多重利好共振。另一方面，AI制药订单持续落地驱动生命科学上游需求攀升，板块整体景气度回暖。此外，再生元Libtayo获加拿大卫生部批准用于高危皮肤鳞状细胞癌辅助治疗，进一步提振市场情绪。该ETF追踪纳斯达克生物医疗指数，包含在纳斯达克上市的生物医疗公司，成分和权重可能随时间变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660585446","title":"瑞穗上調安進目標價至352美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660585446","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660585446?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:55","pubTimestamp":1787129710,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IBBQ","LU2112291526.USD","LU0289739699.SGD","LU2089984988.USD","PBE","PJP","AMGN","BK4534","LU1061106388.HKD","BK4599","BIB","BK4533","LU0109394709.USD","LU0320765992.SGD","LU1057294990.SGD","LU1571399168.USD","BBH","TBXU","LU1023059063.AUD","LU0868494617.USD","LU0889565916.HKD","BK4588","IBB","LU2468319806.SGD","LU0122379950.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4139","IE00B2B36J28.USD","IE0009355771.USD","SG9999001440.SGD","BK4585","BK4566","UUP","BK4581","LU2242652126.USD","UDN","LU2242646821.SGD","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431564","title":"駿利亨德森投資：專利到期倒逼藥企擴張 生物科技併購、IPO市場同步復甦","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431564","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660431564?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:06","pubTimestamp":1787126785,"startTime":"0","endTime":"0","summary":"骏利亨德森投资称，尽管利率较市场年初的预期为高，但生物科技行业交易活动的增长动力持续不减。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["JDOC","PBE","IAI","BBC","BK4588","BIS","IBB","IWO","BK4582","FBT","IBBJ","QSML","BBP","IJT","MRNX","GTPE","MRNY","SPCK","IYG","BIB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660416851","title":"藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2660416851","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660416851?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 09:48","pubTimestamp":1787104101,"startTime":"0","endTime":"0","summary":"湘雅二医院方面向澎湃新闻表示，院方确有发该“协办函”。据此次公布的协办函，对几家涉事药企的处理决定颇为严厉。近年来，医药代表违规已不仅是行业道德问题，而是监管重点。此次湘雅二医院将企业列入购销负面清单，正是医院端落地上述政策的缩影。湘雅二医院相关负责人表示，自国家在2020年底建立医药代表备案制度，医院就积极响应国家政策，并不断完善内部制度和执行流程。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787103396417327872","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2112291526.USD","SG9999001440.SGD","LU1057294990.SGD","LU2468319806.SGD","BIB","IE0009355771.USD","688578","LU2089984988.USD","BK4588","AMGN","LU0289739699.SGD","PBE","LU1061106388.HKD","LU0320765992.SGD","BBH","BK0239","IE0002141913.USD","IE00BFTCPJ56.SGD","TBXU","IE00B4R5TH58.HKD","LU2242652126.USD","LU0122379950.USD","IBB","PJP","BK4581","IE00BJJMRZ35.SGD","BK4139","BK4599","BK4533","LU2242646821.SGD","LU0889565916.HKD","LU1983299246.USD","LU1571399168.USD","BK4585","LU0109394709.USD","LU0868494617.USD","LU1023059063.AUD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IBBQ","LU0058720904.USD","BK4534","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192416297","title":"TScan Therapeutics披露：安進將終止與其研究合作及許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1192416297","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192416297?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 05:04","pubTimestamp":1787087050,"startTime":"0","endTime":"0","summary":"值得注意的是，安进作为全球领先的生物制药公司，此举无疑将对TScan Therapeutics的研发管线及未来战略布局产生深远影响。TScan Therapeutics方面表示，将仔细评估这一变化对公司在研项目及整体运营带来的潜在影响。对于TScan Therapeutics而言，此番变故或许意味着需要重新校准其研发路径，并探索新的合作机会或资金来源以继续推进其创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","BK4534","IE0002141913.USD","BK4566","LU0122379950.USD","LU2468319806.SGD","BBH","BK4539","LU2112291526.USD","BK4533","IE00B4R5TH58.HKD","AMGN","LU1571399168.USD","BK4581","BK4599","IE00BJT1NW94.SGD","BK4585","LU0058720904.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2242646821.SGD","LU0868494617.USD","IBB","PBE","LU0889565916.HKD","BIB","LU1057294990.SGD","BK4588","LU1061106388.HKD","BK4139","LU1983299246.USD","IBBQ","PJP","LU2242652126.USD","LU0109394709.USD","LU1023059063.AUD","LU2089984988.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","TCRX","LU0289739699.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660491619","title":"吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660491619","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660491619?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 02:16","pubTimestamp":1787076999,"startTime":"0","endTime":"0","summary":"• 联邦法院禁令阻止了吉利德关键HIV药物的海外进口。\n• 强劲的基础业务营收增长与上调业绩指引提振了市场乐观情绪。\n• 肿瘤领域的战略投资及机构看涨期权活动的活跃支撑了股价的上涨势头。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262115765-market-movers-gild-20260818","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","IBB","MEDI","SG9999015952.SGD","GILD","LU1061106388.HKD","LU1934455863.HKD","BK4532","LU1023059063.AUD","BK4550","LU2087621335.USD","IE00BKVL7J92.USD","LU0058720904.USD","LU0965509101.SGD","LU2324357040.USD","IE00B7SZLL34.SGD","LU0965508806.USD","BK4583","LU1037948897.HKD","TBXU","LU0320765992.SGD","LU1430594728.SGD","LU0289739699.SGD","LU0109394709.USD","LU1037948541.HKD","SG9999015978.USD","IE00B19Z3581.USD","SG9999015986.USD","BMED","LU0114720955.EUR","BK4585","LU1066053197.SGD","LU1778281490.HKD","IE00BZ1G4Q59.USD","BK4566","LU1674673428.USD","IE00B3T34201.USD","LU2112291526.USD","LU1674673691.USD","BK4578","LU2089984988.USD","BIB","LU0823416689.USD","IBBQ","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU1839511570.USD","LU1571399168.USD","BBH","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660439442","title":"argenx SE(ARGX)股票8月17日盤中上漲16.67%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2660439442","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660439442?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 00:16","pubTimestamp":1786983373,"startTime":"0","endTime":"0","summary":"• Argenx 宣布其药物 VYVGART Hytrulo 在治疗肌炎的 3 期 ALKIVIA 研究中取得积极结果。\n• 该公司公布全年营收为 41.5 亿美元，净利润为 12.9 亿美元。\n• 分析师给予“买入”评级，平均目标价为 1083.77 美元。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262112725-market-movers-argx-20260817","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU0109394709.USD","FMED","IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","LU1983260115.SGD","IE0034235188.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2324357040.USD","IE0002141913.USD","IE00B2B36J28.USD","IBB","BK4505","LU0823416689.USD","IE00B4R5TH58.HKD","BK4588","ARGX","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332334","title":"EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332334","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332334?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 22:15","pubTimestamp":1786976114,"startTime":"0","endTime":"0","summary":"BUZZ-EyePoint股价料将创下历史最大跌幅，因其一款实验性眼科药物未能达到后期临床试验目标最新动态8月17日-**EyePoint公司（EYPT.O）股价暴跌71%至4.17美元，有望创下有史以来最大单日跌幅，并跌至2025年4月以来的最低点**这家药物开发商表示，其实验性眼科药物Duravyu在针对湿性年龄相关性黄斑变性（视力丧失的主要原因之一）患者开展的晚期临床试验中，未能达到主要目标","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","LU2106854487.HKD","BK4007","LU2362541273.HKD","LU0058720904.USD","LU2468319806.SGD","LU2089984988.USD","LU2237438978.USD","LU1974910355.USD","BK4588","IBB","EYPT","LU0320765992.SGD","LU0823434740.USD","LU0289739699.SGD","LU2023250504.SGD","LU2362541513.USD","LU0053666078.USD","TBXU","LU0114720955.EUR","LU0823416689.USD","LU2362540622.SGD","LU0823434583.USD","BK4139","BBH","IBBQ","REGN","LU1917777945.USD","LU0882574055.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137019504","title":"美股開盤 | 三大指數升跌不一，閃迪升逾3%，Argenx SE漲近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137019504","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137019504?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 21:32","pubTimestamp":1786973544,"startTime":"0","endTime":"0","summary":"8月17日，美股三大指数开盘涨跌不一，道琼斯指数跌0.23%，标普500指数涨0.04%，纳斯达克综合指数涨0.24%。美股存储股普涨，SK海力士、西部数据、闪迪涨超3%，美光科技、希捷科技涨超2%。OmniAb涨超23%，公司此前宣布与礼来达成3.7亿美元药物研发协议。Argenx SE涨近9%，Efgartigimod治疗肌炎III期试验成功。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WUGI","LU0476273544.USD","MEDX","LU2756315664.SGD","SGXZ51526630.SGD","SKHZ","LU0820561818.USD","SKUU","IE00BFSS8Q28.SGD","LU1267930730.SGD","LU2361044949.HKD","FXL","LU0823434740.USD",".DJI","LU0889565916.HKD","LU1914381329.SGD","LU1127390331.HKD","ILDR","QQQA","IHE","DDM","BOBP","LU2286300806.USD","LU2168564149.EUR","IE0009356076.USD","LU0444973449.USD","LU1815336760.USD","WLDR","BK4543","LU1917777945.USD","TMSL","LU2360106780.USD","IE00BWXC8680.SGD","GDOC","IE0001KFT4U8.USD","VOO","LU0210536198.USD","LU1064131342.USD","LU0432979614.USD","LU2089284900.SGD","LU1145028129.USD","LU0133085943.USD","SNDK","BK4007","LU2746668461.USD","CURE","BK4516","BK4554","LU1674673428.USD","THNR","BK7142","CANC","CHAT","IE0004445239.USD","LU2054465674.USD","IE00B19Z9Z06.USD","CHPS","LU1868836591.USD","DOG","LU0127658192.USD","LU2491050154.USD","LU2112291526.USD","SG9999013999.USD","FAI","VHT","LU0320765992.SGD","LU0859254822.USD","LU0882574139.USD","LU0203347892.USD","LU1674673691.USD","LU2063271972.USD","SG9999001176.SGD","IE00BSNM7G36.USD","BK4512","SG9999014898.SGD","LU0345770308.USD","BK4588","LU0256863811.USD","LU0889566641.SGD","LU0820561909.HKD","LU2468319806.SGD","SG9999014880.SGD","LU1235294995.USD",".SPX","LU0787776722.HKD","DMAX","LU0240877869.USD","SPYU","LU2111349929.HKD","MUD","LU1974910355.USD","SG9999018857.SGD","WDNA","LU0792757196.USD","LU2168564065.EUR","BK4139","LU2491050071.SGD","LU2471134952.CNY","CGGO","LU1035773651.USD","LU2168563687.JPY","LU0316494557.USD","IE00B19Z3581.USD","LU2237443465.HKD","UDOW","IVV","LU2462157665.USD","LU2896262040.SGD","LU0109394709.USD","SG9999015986.USD","BK4141","LU1814569148.SGD","LU2360107168.USD","LU0640476718.USD","IE0002141913.USD","LU2236285917.USD","LU0198837287.USD","ELIL","LU1979441026.SGD","IE00B894F039.SGD","LU2237443978.SGD","LU0158827781.USD","LU0082616367.USD","JGRO","MUZ","PTF","IE00BJJMRY28.SGD","LU2458330169.SGD","FTXH","LU2237443382.USD","LU0353189680.USD","LU0174119429.USD","LU2108987350.USD","IE00BJJMRX11.SGD","SDS","LU1267930813.SGD","LU0158827948.USD","SPDN","IE0009355771.USD","LU0274383776.USD","FDTX","EGGY","LU1629891620.HKD","IE00BJT1NW94.SGD","SNDG","SG9999017495.SGD","SG9999014906.USD","JDOC","BK4532","IE00B4JS1V06.HKD","TMED","LU1280957306.USD","LU1023059063.AUD","BK4605","XNTK","LU0719512351.SGD","HYNX","YSPY","STX.AU","LU2237443895.HKD","BAI","IE00BN29S564.USD","LU0006061336.USD","SG9999001176.USD","LU2237438978.USD","WDC","LU1988902786.USD","LU1093756168.USD","LU0072461881.USD","LU2089985449.USD","FCUS","LU0964807845.USD","LU1868836757.USD","SKDD","LU0154236417.USD","LU1069344957.HKD","LU1720051017.SGD","LU0054578231.USD","SNDU","LLYZ","LU0203202063.USD","SPXU","TTXU","LU2750360641.GBP","DXD","LU1720051108.HKD","LU2048586759.USD","SG9999015945.SGD","LU0456855351.SGD","LU0006306889.USD","LU2471134523.USD","LU0471298777.SGD","IE0002270589.USD","IE00BKPKM429.USD","LU2552382132.HKD","SPYQ","SG9999001424.SGD","LEGR","LU0889565833.HKD","LU1861220033.SGD","LU2271345857.HKD","IE0034235188.USD","IE00BFTCPJ56.SGD","IE00BJLML261.HKD","IE00B5949003.HKD","LU2931357623.SGD","SSO","CNEQ","LU1323610961.USD","LU1989764748.USD","BK4579","LU0444971666.USD","SOXX","LU0943347566.SGD","LU2211815571.USD","IE00B7SZLL34.SGD","IE00BJJMRZ35.SGD","QQQG","GB00BDT5M118.USD","LU0096364046.USD","LU0122379950.USD","SG9999014914.USD","STX","LU0106261372.USD","SDOW","IE00B1BXHZ80.USD","FMED","PPH","LU2213496289.HKD","LU2746668974.SGD",".IXIC","SH","LU0266013472.USD","LU1989764664.SGD","PJP","LU2028103732.USD","MUU","LU1861215975.USD","OPTZ","TBXU","LU1551013425.SGD","SGXZ57979304.SGD","LU0353189763.USD","SPY","DRMY","SMH","SMU00main","AIFD","LU0786609619.USD","SCHA","MULL","LU2360106947.USD","ARGX","PSI","LU0323591593.USD","SG9999015978.USD","LU2290526834.HKD","YMmain","LU2023250330.USD","SOXQ","LU0256863902.USD","LU2250418816.HKD","LU1868837300.USD","ELIS","LU0385154629.USD","SNDC","IXN","BK4505","LU2361044865.SGD","LU1868836914.USD","SGXZ81514606.USD","LU2023250504.SGD","IETC","LU2102340556.USD","LU0823416689.USD","LU0162691827.USD","LU1057294990.SGD","AIS","LU1778281490.HKD","BK4553","LU0056508442.USD","LU2543165471.USD","DIA","LU1670627923.USD","BK4575","LU2168564222.USD","LU2168564495.EUR","LU1868837136.USD","LU0234572021.USD","DISK","IXJ","IE00B1XK9C88.USD","LU2458330243.SGD","SCHM","LU0240878834.USD","LU2461242641.AUD","LU0345770993.USD","LU1046421795.USD","LU0708995401.HKD","EFIV","IE00B7KXQ091.USD","LU1035775433.USD","LU2462591350.SGD","LLII","LU2106854487.HKD","IE00B4R5TH58.HKD","VGT","LU2750360997.AUD","XLK","LU2265009873.SGD","LU2357305700.SGD","AGNG","UPRO","IE00BK4W5L77.USD","TRFK","LU1670628061.USD","SGXZ99366536.SGD","LU0109392836.USD","LU1804176565.USD","OZEM","SK","TRUH","LU1366333091.USD","SKHYV","SPYH","SKHX","LU2089283258.USD","WDCX","IE0034235303.USD","LU2361045086.USD","LU1232071149.USD","SPYM","RXL","LU0820562030.AUD","LU0114720955.EUR","LU0689472784.USD","MIC","IE000M9KFDE8.USD","COWG","IE00BKDWB100.SGD","LU2087625088.SGD","IE00BK4W5M84.HKD","LU0203201768.USD","LU2456880835.USD","LU1803068979.SGD","LU0823434583.USD","IE00BFSS7M15.SGD","LU0097036916.USD","SG9999015952.SGD","FTXL","SPXS","LU1551013342.USD","LU0683600562.USD","AIQ","LU1823568750.SGD","FSMD","LU2602419157.SGD","LU0079474960.USD","LU0957808578.USD","LU2403377893.USD","SNDQ","LU0081259029.USD","BK4581","USXF","LU2023251221.USD","BK4585","LU0417517546.SGD","SKHA","HBMX","BK4566","LU0061475181.USD","IE0004445015.USD","LU1712237335.SGD","LU2089984988.USD","LLYX","IE00B19Z3B42.SGD","LU1061106388.HKD","SMAX","RULE","LU1989771016.USD","LU1548497426.USD","MEDI","LU1291159041.SGD","LU0882574055.USD","HIBL","LU1983260115.SGD","BK4533","CNAV","LU0203345920.USD","LU0354030511.USD","LU2417539215.USD","SHOC","LU2552382058.USD","LU0058720904.USD","MU","XLV","SG9999018865.SGD","LU0320765059.SGD","EMSF","IE0005OL40V9.USD","LU1852331112.SGD","LU2264538146.SGD","LU0289739699.SGD","FHLC","LLY","LU0471298694.HKD","MUYY","BK4534","LU0157215616.USD","IYH","LU2471134796.USD","SPUU","LU0642271901.SGD","LU0238689110.USD","BK4170","BK4599","LU0094547139.USD","MHIP","LU1642822529.SGD","LU2237443622.USD","LU1316542783.SGD","SKHU","LU1983299246.USD","LU0466842654.USD","IBB","ARTY","LU2552382215.SGD","FTEC","MMAX","LU2756315318.SGD","LU1366192091.USD","LU0354030438.USD","LU0225283273.USD","LU1069347547.HKD","SKHY","BK4527","IE00B2B36J28.USD","LU2491049909.HKD","SNXX","LU2357627491.SGD","IE00B19Z9P08.USD","SGXZ31699556.SGD","HRTS","LU1093756325.SGD","SPXL","LU0109391861.USD","IE00B775H168.HKD","LU1623119135.USD","LU2471134879.HKD","CHPX","LU2324357040.USD","LU0963586101.USD","07709","LU2237443549.SGD","LU0672654240.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848445","title":"EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848445","media":"路透中文","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848445?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:14","pubTimestamp":1786965255,"startTime":"0","endTime":"0","summary":"EyePoint公司未能证明Duravyu在保护视力方面不比Eylea明显逊色。而在接受Eylea治疗的患者中，未出现此类情况。EyePoint的股价在早盘交易中跌至4.16美元。EyePoint计划于2027年上半年向美国FDA提交批准申请，具体取决于预计于今年晚些时候公布的第二项晚期临床试验结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E0O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1974910355.USD","LU0058720904.USD","LU2023250504.SGD","EYPT","LU2089984988.USD","LU2362541513.USD","LU0823434583.USD","BBH","LU2362540622.SGD","LU2468319806.SGD","LU2106854487.HKD","LU0823434740.USD","LU0882574055.USD","REGN","OTLK","LU0889565916.HKD","LU2237438978.USD","BK4585","LU0114720955.EUR","TBXU","LU0823416689.USD","IBBQ","LU0320765992.SGD","BK4139","IBB","LU0289739699.SGD","LU2362541273.HKD","BK4007","LU0053666078.USD","LU0109394709.USD","BK4588","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481020","title":"美股異動 | Argenx(ARGX.US)盤前升逾10% 自身免疫性肌炎藥物Vyvgart III期研究達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660481020?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:48","pubTimestamp":1786963699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARGX","TBXU","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0889565916.HKD","BK4134","IE00BFTCPJ56.SGD","FMED","LU1983260115.SGD","BK4588","IE0034235188.USD","BK4585","IE00BJJMRZ35.SGD","IBB","LU0823416689.USD","IE0002141913.USD","BK4139","LU0320765992.SGD","III","IE00B4R5TH58.HKD","IE0009355771.USD","LU2324357040.USD","BK4505","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848605","title":"美股異動丨Argenx SE盤前大升逾7%，Efgartigimod治療肌炎III期試驗成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848605","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848605?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:37","pubTimestamp":1786959424,"startTime":"0","endTime":"0","summary":"Argenx SE(ARGX.US)盘前涨超7%，报913.38美元。消息面上，公司宣布，Efgartigimod在治疗自身免疫性肌炎的III期ALKIVIA试验中达到了主要终点。在52周时，与安慰剂相比，药物在总改善评分(TIS) 上实现了具有统计学和临床意义的改善。此次试验成功对Argenx意义重大，开辟新市场：自身免疫性肌炎在美国影响约10万人，其中IMNM约2万，DM约4万，这是一个尚未被满足的巨大医疗市场。公司计划为IMNM提交加速审批申请，并将与FDA讨论DM的申报可能性。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IE00BFTCPJ56.SGD","LU1983260115.SGD","BK4505","IE0002141913.USD","LU2324357040.USD","LU0889565916.HKD","FMED","BK4585","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0034235188.USD","LU0823416689.USD","TBXU","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4139","IBB","LU0109394709.USD","BK4134","BK4588","IE0009355771.USD","IE00BJT1NW94.SGD","ARGX","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660866704","title":"復星醫藥子公司攜生物類似藥出海 牽手全球仿製藥龍頭，鎖定四成銷售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2660866704","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660866704?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:26","pubTimestamp":1786958770,"startTime":"0","endTime":"0","summary":"8月17日，复星医药（SH600196，股价24.01元，市值588.9亿元）公告披露，其控股子公司复宏汉霖与全球生物类似药龙头SandozAG于8月16日签订《合作框架协议》。双方约定，可就复宏汉霖至多10款单克隆抗体（mAb）和/或抗体偶联药物（ADC）生物类似药，开展海外区域的注册、商业化、开发、生产等许可合作，并已就首批3款产品达成具体商业条款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843260444.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843260444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","LU2322448791.USD","BK1593","BK0012","LU1992135399.USD","XPH","PPH","600196","BK0028","BK4588","LU2272731865.HKD","LU1992135472.HKD","02196","BK0239","BK1515","IE00B5TLWC47.USD","IBB","BK0196","BK0183","LU2272731600.USD","BK0187","LU2322448957.HKD","BK4585","BK0060","BK0096","BK0188","BK1191","LU2473716301.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660857514","title":"復宏漢霖與山德士達成戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2660857514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660857514?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:05","pubTimestamp":1786957508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XPH","IBB","IE00B5TLWC47.USD","BK4585","LU1992135472.HKD","LU2272731600.USD","LU2322448791.USD","LU2322448957.HKD","LU2473716301.USD","PPH","LU1992135399.USD","LU2272731865.HKD","LU2272731782.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660853994","title":"argenx SE（ARGX）宣佈Efgartigimod治療自身免疫性肌炎的3期ALKIVIA試驗取得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660853994","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660853994?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:43","pubTimestamp":1786956188,"startTime":"0","endTime":"0","summary":"该试验评估了皮下注射药物VYVGART Hytrulo在成人自身免疫性肌炎中的疗效，包括免疫介导的坏死性肌病和皮肌炎。在IMNM亚组分析中，治疗组同样展现出14.8分的显著改善。这是全球首个在没有任何批准疗法的IMNM领域取得统计学显著与临床意义改善的三期临床试验。自身免疫性肌炎属于罕见且高度致残的疾病，长久以来临床严重依赖大剂量激素和广谱免疫抑制剂。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303846","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FMED","IE0034235188.USD","IE00BFTCPJ56.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00B2B36J28.USD","BK4505","LU1983260115.SGD","BK4139","TBXU","IE00BJT1NW94.SGD","BK4585","BK4588","LU0823416689.USD","LU0320765992.SGD","IE0009355771.USD","IBB","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","ARGX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}